[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer

FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET

NCT03726931 ·Status: COMPLETED ·Phase: NA

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

NCT02409316 ·Status: COMPLETED ·Phase: PHASE2

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer

NCT03768479 ·Status: UNKNOWN ·Phase: NA

Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma

NCT05960201 ·Status: COMPLETED ·Phase: PHASE2

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

NCT05541367 ·Status: RECRUITING

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

NCT02149173 ·Status: TERMINATED ·Phase: NA

18F-fluoroestradiol (FES) PET/CT for Breast Cancer

NCT04883814 ·Status: UNKNOWN ·Phase: PHASE2

Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation

NCT03544762 ·Status: UNKNOWN ·Phase: PHASE3

Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer

NCT07316439 ·Status: ACTIVE_NOT_RECRUITING

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

NCT03065712 ·Status: WITHDRAWN ·Phase: PHASE2

Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor

NCT06344767 ·Status: COMPLETED

Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer

NCT03442504 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

NCT06557148 ·Status: RECRUITING

Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES

NCT03873428 ·Status: RECRUITING ·Phase: NA

16α-18F-fluor-17β-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer

NCT04150731 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.

NCT03619044 ·Status: TERMINATED ·Phase: NA

18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients

NCT06655545 ·Status: COMPLETED

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

NCT04692103 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

FDG PET-CT in Advanced Breast Cancer

NCT07173868 ·Status: RECRUITING

Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer

NCT03507088 ·Status: COMPLETED ·Phase: NA

Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer

NCT04411966 ·Status: COMPLETED ·Phase: NA

18F FES-PET/MRI for Tailoring Treatment of Luminal a and Lobular Breast Cancer

NCT05982496 ·Status: NOT_YET_RECRUITING ·Phase: NA

Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor

NCT05797987 ·Status: COMPLETED

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

NCT05486182 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer

NCT05088785 ·Status: RECRUITING ·Phase: NA